Results 61 to 70 of about 15,205 (209)

The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective. [PDF]

, 2016
AIMS: Heart failure (HF) treatment guided by physicians with access to real-time pressure measurement from a wireless implantable pulmonary artery pressure (PAP) sensor (CardioMEMS), has previously been shown to reduce HF-related hospital admissions in ...
Abraham, Abraham, Adamson, Adamson, Berg, Boyne, Braunschweig, Briggs, Chaudhry, Cleland, Cleland, Cotter, Curtis, Drummond, Gheorghiade, Griffiths, Inglis, Jeon, Jhund, Kato, Klersy, Koehler, Martinson, Matza, Mitchell, Mosterd, Ong, Pandor, Ponikowski, Sandhu, Schiff, Thokala, Townsend   +32 more
core   +2 more sources

Machine learning‐based prediction of elevated N terminal pro brain natriuretic peptide among US general population

ESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.
Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori, Shingo Fukuma, Kyohei Yamaji, Atsushi Mizuno, Naoki Kondo, Kosuke Inoue   +5 more
wiley   +1 more source

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction

ESC Heart Failure, 2021
Aims Despite well‐established benefits of sacubitril/valsartan for cardiac reverse remodelling and the prognosis of patients with heart failure with reduced ejection fraction (HFrEF), there are some patients with limited therapeutic response, even with ...
Mi‐Gil Moon, In‐Chang Hwang, Wonsuk Choi, Goo‐Yeong Cho, Yeonyee E. Yoon, Jun‐Bean Park, Seung‐Pyo Lee, Hyung‐Kwan Kim, Yong‐Jin Kim   +8 more
doaj   +1 more source

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization [PDF]

, 2016
Purpose: Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA class II ...
Iris Rajman, Jesika Petruck, Kiran Kode, Parasar Pal, Pierre Jordaan, Priya Chandra, Soniya Vaidya, Thomas H. Langenickel   +7 more
core   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice

Frontiers in Endocrinology, 2022
Treatment of heart failure with the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan improved glycemic control in individuals with type 2 diabetes. The relative contribution of neprilysin inhibition versus angiotensin II receptor antagonism
Nathalie Esser, Nathalie Esser, Nathalie Esser, Christine Schmidt, Breanne M. Barrow, Laura Cronic, Daryl J. Hackney, Stephen M. Mongovin, Meghan F. Hogan, Meghan F. Hogan, Andrew T. Templin, Andrew T. Templin, Joseph J. Castillo, Joseph J. Castillo, Rebecca L. Hull, Rebecca L. Hull, Sakeneh Zraika, Sakeneh Zraika   +17 more
doaj   +1 more source

Monitoring of biomarkers in heart failure. [PDF]

, 2019
The role of biomarkers is increasingly recognized in heart failure (HF) management, for diagnosis, prognostication, and screening of high-risk patients.
Agewall, Agewall, Agewall, Agostoni, Andrew J S Coats, Ather, Bayes-Genis, Bhambhani, Binas, Broch, Demissei, Felker, Giuseppe M C Rosano, Graham, Greene, Hallén, Harjola, Hoedemaker, Ilaria Spoletini, Januzzi, Januzzi, Ky, McCarthy, Michele Senni, Mueller, Nadar, O'Meara, Pareek, Paul, Peacock, Perk, Ponikowski, Rastogi, Salmonson, Sarhene, Sato, Schneider, Shah, Squire, Stenemo, Tamargo, Troughton, Welsh, Xue   +43 more
core   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Natriuretic Peptides in the Cardiovascular System. Multifaceted Roles in Physiology, Pathology and Therapeutics [PDF]

, 2019
The natriuretic peptides (NPs) family includes a class of hormones and their receptors needed for the physiological control of cardiovascular functions. The discovery of NPs provided a fundamental contribution into our understanding of the physiological ...
Rubattu, Speranza, Volpe, Massimo
core   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source